Application of panax notoginseng polysaccharide in preparation of medicine for promoting wound healing

Abstract

The invention belongs to the field of medicines, and discloses application of panax notoginseng polysaccharide in preparation of a medicine for promoting skin wound healing. Wherein the panax notoginseng polysaccharide is an active ingredient in the medicine for promoting skin wound healing, and the content of the panax notoginseng polysaccharide is preferably 200mg / ml. The invention also provides a pharmaceutical composition. The pharmaceutical composition is prepared from the active component pseudo-ginseng polysaccharide and one or more pharmaceutically acceptable carriers or excipients. The pharmaceutical composition can also contain one or more other active ingredients with similar effects. The pharmaceutical composition can be in various dosage forms such as cream, emulsion, ointment, aerosol or solution. The pharmaceutical composition has the effect of remarkably promoting microvascularization, and the healing speed of skin wounds can be remarkably increased.

Description

Technical Field

[0001] The invention relates to application of a medicinal active ingredient in preparing medicines, in particular to application of notoginseng polysaccharide in preparing medicines, and belongs to the technical field of medicines. Background Art

[0002] The wound healing process of the human body is affected by many external factors, including wound size, age, health status, etc. In clinical practice, the commonly used trauma treatment methods currently include skin transplantation, suturing, debridement, antibacterial, etc., but these methods cannot effectively promote wound healing, and there is still a lack of methods and drugs with obvious promoting effects.

[0003] The treatment of wound healing has always been plagued by the following problems: first, the risk of wound infection; second, the repair and reconstruction of wound tissue; and third, the beauty and functional recovery of the skin. Wound infection can lead to inflammatory responses, delay wound healing, and even cause serious complications such as sepsis. The repair and reconstruction of wound tissue requires the coordination and balance of multiple biological processes such as angiogenesis, cell migration, and matrix deposition. If these processes are disturbed or dysregulated, it will cause delayed healing or scar formation. After the wound heals, it is often difficult for the skin to return to its original shape, so the beauty and functional recovery of the skin are also very important.

[0004] Panax notoginseng is a herbaceous plant of the Araliaceae family. It contains saponins, volatile oils, flavonoids, polysaccharides and other effective ingredients. It is widely used in clinical treatments of cardiovascular diseases, cerebrovascular diseases, blood, nerves, immune system, wound healing, etc. The total amount of polysaccharides in Panax notoginseng accounts for about 9.45%, but to date, there are few basic research reports on the application of its important component Panax notoginseng polysaccharide in wound repair. Studies have shown that Panax notoginseng polysaccharide has a promoting effect on the cellular immune function of traumatic rats, suggesting that Panax notoginseng polysaccharide has a certain effect on wound repair. Through systematic research on the promoting effect of Panax notoginseng polysaccharide on wound healing in rats, it was found that Panax notoginseng polysaccharide can significantly reduce inflammatory response, significantly improve the speed and quality of wound healing, and promote the progress of wound healing in rats. It provides a new option for wound treatment.

[0005] The invention can be used in the form of an additive in the healing of skin wounds and can be made into various dosage forms such as creams, emulsions, ointments, aerosols, solutions, etc. that promote wound healing. Summary of the invention

[0006] The present invention discovers the application of Panax notoginseng polysaccharide in preparing a medicine for promoting skin wound healing.

[0007] Among them, Panax notoginseng polysaccharide is the active ingredient in drugs that promote skin wound healing, and its content is 200mg / ml.

[0008] The medicine of the present invention is prepared into a pharmaceutical composition by combining active ingredients with one or more pharmaceutically acceptable carriers or excipients.

[0009] The medicine of the present invention may also contain one or more other active ingredients having similar effects.

[0010] Wherein, the wound healing promoting drug can be a cream, emulsion, ointment, aerosol or solution.

[0011] The present invention has conducted animal experiments and found for the first time that Panax notoginseng polysaccharide has a significant effect of promoting wound healing, especially skin wound healing. Through animal experiments, it was found that Panax notoginseng polysaccharide has a significant effect of promoting microvascular formation and can significantly accelerate the healing speed of skin wounds.

[0012] The dosage form of the present invention can be produced by any method conventionally used in pharmaceutical preparation technology without particular limitation.

[0013] The notoginseng polysaccharide described in the application of the present invention can promote skin wound healing and can be used in the form of any additive. The skin external composition, mixture or compound containing the active ingredient notoginseng polysaccharide of the present invention can be made into various dosage forms such as creams, emulsions, ointments, aerosols, solutions, etc. that promote skin wound healing.

[0014] Specifically, the preferred technical solution of the present invention is:

[0015] Application of Panax notoginseng polysaccharide in the preparation of drugs for promoting wound healing, especially promoting skin wound healing.

[0016] The application of Panax notoginseng polysaccharide in the preparation of a drug for promoting skin wound healing, wherein Panax notoginseng polysaccharide is used as an active ingredient in the drug. Preferably, the content of Panax notoginseng polysaccharide is 150-250 mg / ml, and most preferably 200 mg / ml.

[0017] A pharmaceutical composition is prepared from an active ingredient, Panax notoginseng polysaccharide, and one or more pharmaceutically acceptable carriers or excipients.

[0018] The pharmaceutical composition may also contain one or more other active ingredients with similar effects.

[0019] The pharmaceutical composition can be in various dosage forms such as cream, emulsion, ointment, aerosol or solution.

[0020] The pharmaceutical composition has an obvious effect of promoting the healing of skin wounds.

[0021] The pharmaceutical composition has the effect of significantly promoting the formation of microvessels and can significantly accelerate the healing speed of skin wounds. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 :Effects of Panax notoginseng polysaccharide on wound healing in rats

[0023] Figure 2 Effect of Panax notoginseng polysaccharide on wound healing rate in rats

[0024] Figure 3 :Effects of Panax notoginseng polysaccharide on blood flow changes in wounds of rats

[0025] Figure 4 :Effects of Panax notoginseng polysaccharide on microangiogenesis in wounds of rats

[0026] Figure 5 :Effects of Panax notoginseng polysaccharide on microvascular parameters of wounds in rats

[0027] Figure 6 :Effects of Panax notoginseng polysaccharide on pathological morphology of wounds in rats

[0028] Figure 7 :Effect of Panax notoginseng polysaccharide on collagen reconstruction in rat wounds

[0029] Figure 8 :Effects of Panax notoginseng polysaccharide on wound scar in rats DETAILED DESCRIPTION

[0030] The present invention is further described in detail below with reference to specific embodiments.

[0031] Example 1: Study on the effect of Panax notoginseng polysaccharide on promoting wound healing in rats

[0032] Establishment of rat trauma model

[0033] Adult male Wistar rats (Beijing Weitonglihua, Beijing, China) were acclimated to ventilated cages (temperature 20-25℃, relative humidity 30%-50%) under a 12-h light-dark cycle and given free access to food and water. Thirty-two rats were randomly divided into five groups: model control group; notoginseng polysaccharide 50 mg / kg group; notoginseng polysaccharide 100 mg / kg group; notoginseng polysaccharide 200 mg / kg group. A circular stamp with a diameter of 20 mm or a radius of 10 mm was used to make circular marks on both sides of the spine of Wistar rats. Full-thickness skin (up to the deep fascia layer) was cut along the marks with surgical scissors, and two circular full-thickness skin defect wounds were made on the back of each rat. The animals were housed in single cages and the drug was administered once a day after injury for 14 consecutive days.

[0034] Observation of wound healing

[0035] Images were taken on days 0, 3, 7, and 14 to observe the wound healing conditions of each group at different times. Figure 1The wound was covered with a transparent plastic film and the wound was described along its edge with a marker. Subsequently, the transparent plastic film pattern was scanned, and the pixel value was measured using Image J software and converted into area to obtain the wound healing rate. The results are shown in Figure 2 . Laser Doppler blood flowmeter was used to detect changes in blood supply. The results are shown in Figure 3 Finally, optical coherence tomography angiography was performed, and the results are shown in Figure 4 , and the blood vessel diameter, blood vessel density, blood vessel skeleton density, and blood vessel length were calculated. The results are shown in Figure 5 The wound surface of rats was recorded by photograph at 21 days, and the scar area of ​​rats in each group was calculated by ImageJ software. Figure 8 .

[0036] Pathological section testing

[0037] The full-thickness skin of the wound and the skin around the wound were obtained on days 0, 3, 10, and 14, and the pathological changes of the wound were observed using hematoxylin-eosin (H&E) staining and Masson staining.

[0038] Morphological examination

[0039] After the administration, the animals were anesthetized and the gastric tissue was fixed with 4% formaldehyde. Hematoxylin-eosin staining and Masson staining were performed. Morphological examination was performed under an optical microscope. The results are shown in Figure 3 .

[0040] Plasma collection and biochemical testing

[0041] After the rats were anesthetized, the full-thickness skin was cut with a scalpel along the edge of the unhealed wound at 2 mm, tissue lysis solution was added, and the tissue was cut into pieces on ice with tissue scissors, and then homogenized twice in a tissue homogenizer, each time for 5 min. Then, the tissue fragments were removed by centrifugation at 12000 rpm for 10 min, and the supernatant was sucked out and placed in a centrifuge tube for centrifugation at 14000 rpm for 15 min, and the supernatant was sucked out and the precipitate was discarded. According to the manufacturer's instructions, the commercial detection kit purchased from Lianke (Beijing, China) was used for determination, and the results are shown in Table 1.

[0042] Table 1 Effects of Panax notoginseng polysaccharide on inflammatory factors in wound healing in rats

[0043]

[0044] Figure 6 The effect of Panax notoginseng polysaccharide on the pathological morphology of wounds in rats; Figure 7 The effect of Panax notoginseng polysaccharide on collagen reconstruction in rat wounds; Figure 8 Effect of Panax notoginseng polysaccharide on wound scar in rats

[0045] The animal experiment research conducted by the present invention has found for the first time that Panax notoginseng polysaccharide has the effect of significantly promoting wound healing, especially skin wound healing. Through animal experiment research, it is found that Panax notoginseng polysaccharide has the effect of significantly promoting the formation of microvessels, which can significantly accelerate the healing speed of skin wounds.

Claims

1. Application of Panax notoginseng polysaccharide in the preparation of drugs to promote wound healing.

2. Application of Panax notoginseng polysaccharide in the preparation of drugs for promoting skin wound healing.

3. The use according to claim 1 or 2, characterized in that: In the medicine, Panax notoginseng polysaccharide is the only active ingredient in the medicine.

4. The use according to claim 1 or 2, characterized in that: In the medicine, the content of Panax notoginseng polysaccharide is 150-250 mg / ml.

5. The use according to claim 4, characterized in that: In the medicine, the content of Panax notoginseng polysaccharide is 200 mg / ml.

6. A pharmaceutical composition for promoting wound healing, which is made of the active ingredient Panax notoginseng polysaccharide and one or more pharmaceutically acceptable carriers or excipients.

7. The pharmaceutical composition according to claim 6, further comprises one or more other active ingredients having similar effects.

8. The pharmaceutical composition according to claim 6 or 7, characterized in that The pharmaceutical composition may be in the form of a cream, emulsion, ointment, aerosol or solution.

9. Use of the pharmaceutical composition according to claim 6 or 7 in the preparation of skin wound healing drugs.

10. Use of the pharmaceutical composition according to claim 6 or 7 in the preparation of a drug that significantly promotes microvascular formation and significantly accelerates the healing speed of skin wounds.

Images